SunXPLiJZhuWW, et al.Platelet to lymphocyte ratio predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2018;69(1):71–78.
2.
TepelMvan der GietMSchwarzfeldC, et al.Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180–184.
3.
DurhamJDCaputoCDokkoJ, et al.A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62(6):2202–2207.
4.
ShyuKGChengJJKuanP. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40(8):1383–1388.
5.
KayJChowWHChanTM, et al.Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289(5):553–558.
6.
FishbaneS. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008;3(1):281–287.
7.
Diaz-SandovalLJKosowskyBDLosordoDW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89(3):356–358.
